Efficacy and safety of omalizumab therapy in urticaria vasculitis

Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fiorella, Giannini, Daiana, Bilia, Silvia, Del Corso, Isabella, Rocchi, Valeria, Migliorini, Paola, Puxeddu, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Allergy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353047/
https://www.ncbi.nlm.nih.gov/pubmed/35935020
http://dx.doi.org/10.3389/falgy.2022.952079
Descripción
Sumario:Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclonal antibody, has been successfully used to treat few cases of severe and/or refractory UV. In this study we report our experience on 6 patients with refractory normocomplementemic UV successfully treated with anti-IgE therapy (OMA), suggesting that this biological therapy may be a safe and effective therapeutic option in UV.

Ejemplares similares